Business Context and Reporting Period
This Form 8-K Current Report was filed by Zevra Therapeutics, Inc. (ZVRA) on December 11, 2025. The report discloses a corporate governance change regarding the appointment of an interim Principal Financial Officer effective January 1, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the appointment of Timothy Sangiovanni as the Company's interim Principal Financial Officer. Mr. Sangiovanni, who has served as Senior Vice President, Finance and Corporate Controller since January 2023, will assume the new role effective January 1, 2026. There was no change to his compensation arrangements in connection with this appointment.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the personnel change.
Key Facts for Investor Verification
- Timothy Sangiovanni is appointed as interim Principal Financial Officer effective January 1, 2026.
- Mr. Sangiovanni has been with the company since August 2015, previously serving as Director of Financial Reporting and Vice President, Corporate Controller.
- No compensation changes were made in connection with this appointment.
- The filing contains no financial performance data or forward-looking guidance.